🇺🇸 FDA
Pipeline program

SGT-501

SGT-501-101

Phase 1 small_molecule active

Quick answer

SGT-501 for Catecholaminergic Polymorphic Ventricular Tachycardia is a Phase 1 program (small_molecule) at Solid Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Solid Biosciences
Indication
Catecholaminergic Polymorphic Ventricular Tachycardia
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials